Alle Studien
RekrutierungTherapeutische Erkundung (Phase II)Interventionell

AAA-IPC 2011-003 - Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditioning of allogeneic stem cell transplantation (SCT) from a matched related or unrelated donor in patients with poor prognosis myeloïd malignancies

This study is investigating new ways to treat serious blood cancers that haven't responded well to previous treatments. It focuses on patients receiving a stem cell transplant from a matching donor. Researchers are testing three different doses of a chemotherapy drug called busulfan, along with other anti-cancer medicines (fludarabine and thymoglobuline). The main goal is to find out how long patients live without their cancer getting worse or coming back. They will also look at how effective the treatment is, how new blood cells grow back, and any side effects. This is a Phase II study, meaning it's exploring how well the treatment works and its safety.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Erkundung (Phase II)
Sponsor
Institut Paoli Calmettes
Einschreibeziel
177
Starten
05 Nov 2024

Worum geht es in dieser Studie?

This research study is about finding better ways to treat certain types of serious blood cancers that have a high risk of coming back or haven't responded well to standard treatments. These specific cancers affect the bone marrow, which is where your blood cells are made.

The study involves patients who are having a stem cell transplant. This is a treatment where healthy blood-forming stem cells from a donor (either a family member or an unrelated donor who is a good match) are given to replace unhealthy ones in the patient's bone marrow. Before the transplant, patients need 'conditioning' treatment, which uses strong medicines to prepare their body for the new stem cells.

In this study, doctors are looking at three different amounts (doses) of a chemotherapy drug called busulfan. This is given alongside two other medicines: fludarabine and thymoglobuline. The main aim is to see how long patients live without their cancer growing or returning. They're also carefully watching for side effects, how well the new stem cells settle in and start making healthy blood, and how the body responds to the treatment overall.

Wichtige Erkenntnisse

  • This study is for serious, high-risk blood cancers.
  • It tests different doses of chemotherapy before a stem cell transplant.
  • The main goal is to see how long patients live without their cancer getting worse.
  • It's a Phase II study, exploring effectiveness and safety.
  • Participation involves intensive treatment and close monitoring.

Wer könnte berechtigt sein?

To join this study, you would need to be at least 18 years old, and there is no upper age limit. The study is open to both men and women.

Critically, you must have a specific type of serious blood cancer that doctors consider to be high-risk. This means your cancer might be more difficult to treat or has a higher chance of coming back.

Your doctors would check other detailed medical information to make sure this study is the right fit for your health and cancer type. They would explain all the criteria carefully.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a type of serious blood cancer that is considered high-risk?
  3. Are you able to have a stem cell transplant from a matched donor?
  4. Are you generally well enough for intensive treatment?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part in this study would involve a stem cell transplant, which is a major medical procedure. You would receive the study medications (busulfan, fludarabine, and thymoglobuline) before your transplant. After the transplant, your doctors and nurses would closely monitor your health.

This monitoring would include regular check-ups, blood tests to see how your new blood cells are growing and if the donor cells are working well, and scans to check your cancer. They would also watch for any side effects from the treatment, such as a condition called GvHD (graft-versus-host disease), where the new donor cells react against your body. The follow-up for this study would continue for several months after your conditioning treatment to track your progress and any long-term effects.

Potenzielle Risiken und Vorteile

Participating in a study like this might offer the chance to receive a new treatment approach for your high-risk blood cancer that could be more effective. However, there are also potential risks. Chemotherapy and stem cell transplants are intensive treatments with known side effects, which could be serious. The doctors will carefully watch for these effects and manage them as best they can. It's important to remember that you are free to leave the study at any time, for any reason, without it affecting your medical care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Frankreich

Häufige Fragen

Für welche Art von Krebs ist diese Studie?

This study is for people with serious types of blood cancers that affect the bone marrow and are considered high-risk.

What is a 'stem cell transplant'?

It's a treatment where healthy blood-forming cells from a matched donor replace unhealthy ones in your body, usually after strong chemotherapy.

What are 'conditioning' treatments?

These are strong medicines, like chemotherapy, given before a stem cell transplant to prepare your body for the new cells.

What is 'Phase II' mean in a study?

Phase II means researchers are exploring how well a new treatment works and if it's safe for people, after it's been shown to be safe in a smaller group.

Will I get different medicines if I join this study?

You will receive a standard chemotherapy drug called fludarabine, another medicine called thymoglobuline, and one of three different doses of busulfan.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "AAA-IPC 2011-003 - Prospective and multicentre evaluation of… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.